nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—Retinoids—Tazarotene—psoriasis	0.301	0.5	CiPCiCtD
Bexarotene—Retinoids—Acitretin—psoriasis	0.301	0.5	CiPCiCtD
Bexarotene—RXRB—Tazarotene—psoriasis	0.0835	0.273	CbGbCtD
Bexarotene—RXRG—Acitretin—psoriasis	0.0747	0.244	CbGbCtD
Bexarotene—RXRB—Acitretin—psoriasis	0.066	0.216	CbGbCtD
Bexarotene—RXRA—Acitretin—psoriasis	0.066	0.216	CbGbCtD
Bexarotene—CYP3A4—Calcitriol—psoriasis	0.00222	0.00725	CbGbCtD
Bexarotene—CYP2C9—Cholecalciferol—psoriasis	0.00197	0.00643	CbGbCtD
Bexarotene—CYP3A4—Methoxsalen—psoriasis	0.00172	0.00564	CbGbCtD
Bexarotene—CYP2C9—Cyclosporine—psoriasis	0.00129	0.00422	CbGbCtD
Bexarotene—CYP3A4—Cholecalciferol—psoriasis	0.00114	0.00374	CbGbCtD
Bexarotene—CYP3A4—Triamcinolone—psoriasis	0.000991	0.00324	CbGbCtD
Bexarotene—CYP3A4—Mycophenolate mofetil—psoriasis	0.000991	0.00324	CbGbCtD
Bexarotene—RXRB—Vitamin D Metabolism—VDR—psoriasis	0.00088	0.0472	CbGpPWpGaD
Bexarotene—CYP2C9—Dexamethasone—psoriasis	0.00085	0.00278	CbGbCtD
Bexarotene—CYP3A4—Betamethasone—psoriasis	0.00085	0.00278	CbGbCtD
Bexarotene—CYP3A4—Prednisolone—psoriasis	0.000839	0.00274	CbGbCtD
Bexarotene—CYP3A4—Hydrocortisone—psoriasis	0.000795	0.0026	CbGbCtD
Bexarotene—CYP3A4—Prednisone—psoriasis	0.000792	0.00259	CbGbCtD
Bexarotene—CYP3A4—Cyclosporine—psoriasis	0.000751	0.00245	CbGbCtD
Bexarotene—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000544	0.0292	CbGpPWpGaD
Bexarotene—CYP3A4—Dexamethasone—psoriasis	0.000494	0.00162	CbGbCtD
Bexarotene—RXRA—Vitamin D Metabolism—VDR—psoriasis	0.000459	0.0246	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000436	0.0234	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—REL—psoriasis	0.000419	0.0225	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000413	0.0222	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.00041	0.022	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—REL—psoriasis	0.000394	0.0211	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000389	0.0209	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000388	0.0208	CbGpPWpGaD
Bexarotene—RXRA—REV-ERBA represses gene expression—CARM1—psoriasis	0.000381	0.0205	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000375	0.0201	CbGpPWpGaD
Bexarotene—RXRA—RORA activates circadian gene expression—CARM1—psoriasis	0.000369	0.0198	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.000365	0.0196	CbGpPWpGaD
Bexarotene—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000337	0.0181	CbGpPWpGaD
Bexarotene—RXRA—YAP1- and WWTR1 (TAZ)-stimulated gene expression—CARM1—psoriasis	0.000328	0.0176	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—VDR—psoriasis	0.000322	0.0173	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000304	0.0163	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000304	0.0163	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—VDR—psoriasis	0.000302	0.0162	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000286	0.0153	CbGpPWpGaD
Bexarotene—RXRA—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CARM1—psoriasis	0.00027	0.0145	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000254	0.0136	CbGpPWpGaD
Bexarotene—RXRA—Activation of gene expression by SREBF (SREBP)—CARM1—psoriasis	0.000253	0.0136	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000239	0.0128	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional activation of mitochondrial biogenesis—CARM1—psoriasis	0.000231	0.0124	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—PPARG—psoriasis	0.000224	0.012	CbGpPWpGaD
Bexarotene—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000222	0.0119	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA5—psoriasis	0.000215	0.0116	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000214	0.0115	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—PPARG—psoriasis	0.000211	0.0113	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—REL—psoriasis	0.000205	0.011	CbGpPWpGaD
Bexarotene—RXRA—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CARM1—psoriasis	0.000202	0.0109	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—CARM1—psoriasis	0.000202	0.0109	CbGpPWpGaD
Bexarotene—RXRA—Mitochondrial biogenesis—CARM1—psoriasis	0.000199	0.0107	CbGpPWpGaD
Bexarotene—RXRA—Circadian Clock—CARM1—psoriasis	0.000196	0.0105	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.000195	0.0105	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—VDR—psoriasis	0.00019	0.0102	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000177	0.00951	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—PPARG—psoriasis	0.00017	0.00913	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000167	0.00894	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP2S1—psoriasis	0.000162	0.00867	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000161	0.00866	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—VDR—psoriasis	0.000158	0.00846	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000152	0.00814	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.00015	0.00805	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	0.000149	0.00799	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00014	0.00752	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000138	0.00742	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—SOCS1—psoriasis	0.00013	0.007	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000125	0.00668	CbGpPWpGaD
Bexarotene—RXRG—Regulation of Androgen receptor activity—JUN—psoriasis	0.000122	0.00654	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—CARM1—psoriasis	0.000118	0.00633	CbGpPWpGaD
Bexarotene—RXRB—Regulation of Androgen receptor activity—JUN—psoriasis	0.000115	0.00615	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000114	0.00609	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—CARM1—psoriasis	0.000113	0.00605	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—TARS—psoriasis	0.000112	0.00604	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00011	0.00592	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—PPARG—psoriasis	0.00011	0.0059	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—TARS—psoriasis	0.000106	0.00568	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—LEP—psoriasis	9.62e-05	0.00517	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.43e-05	0.00506	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	9.23e-05	0.00496	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	9.11e-05	0.00489	CbGpPWpGaD
Bexarotene—RXRA—Organelle biogenesis and maintenance—CARM1—psoriasis	9.04e-05	0.00485	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—TNF—psoriasis	9.04e-05	0.00485	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—TGFA—psoriasis	8.99e-05	0.00483	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—PPARG—psoriasis	8.68e-05	0.00466	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—PPARG—psoriasis	8.38e-05	0.0045	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	7.9e-05	0.00424	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	7.61e-05	0.00408	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.49e-05	0.00402	CbGpPWpGaD
Bexarotene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	7.39e-05	0.00396	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—CARM1—psoriasis	7.35e-05	0.00395	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IL6—psoriasis	7.29e-05	0.00391	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	7.17e-05	0.00385	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—CARM1—psoriasis	6.91e-05	0.00371	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.43e-05	0.00345	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—SOCS1—psoriasis	6.39e-05	0.00343	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	6.24e-05	0.00335	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP2S1—psoriasis	6.03e-05	0.00324	CbGpPWpGaD
Bexarotene—RXRA—Regulation of Androgen receptor activity—JUN—psoriasis	5.97e-05	0.00321	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	5.95e-05	0.00319	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—TARS—psoriasis	5.51e-05	0.00296	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—STAT3—psoriasis	5.14e-05	0.00276	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—LEP—psoriasis	4.72e-05	0.00253	CbGpPWpGaD
Bexarotene—RXRA—PPARA activates gene expression—PPARG—psoriasis	4.69e-05	0.00252	CbGpPWpGaD
Bexarotene—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	4.59e-05	0.00247	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.48e-05	0.00241	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TNF—psoriasis	4.45e-05	0.00239	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—VDR—psoriasis	4.39e-05	0.00236	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	4.26e-05	0.00229	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	4.24e-05	0.00228	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—VDR—psoriasis	4.13e-05	0.00222	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—PPARG—psoriasis	4.11e-05	0.0022	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP2S1—psoriasis	3.98e-05	0.00213	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	3.92e-05	0.0021	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.84e-05	0.00206	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—CARM1—psoriasis	3.6e-05	0.00193	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IL6—psoriasis	3.59e-05	0.00193	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—CARM1—psoriasis	3.54e-05	0.0019	CbGpPWpGaD
Bexarotene—CYP3A4—Tryptophan metabolism—CAT—psoriasis	3.43e-05	0.00184	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CARM1—psoriasis	3.39e-05	0.00182	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—CARM1—psoriasis	3.33e-05	0.00179	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	3.32e-05	0.00178	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—NDUFA5—psoriasis	3.25e-05	0.00174	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.23e-05	0.00173	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.17e-05	0.0017	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—PPARG—psoriasis	3.06e-05	0.00164	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.03e-05	0.00163	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—CP—psoriasis	3.02e-05	0.00162	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2.96e-05	0.00159	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—CARM1—psoriasis	2.88e-05	0.00155	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—PPARG—psoriasis	2.88e-05	0.00154	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP2S1—psoriasis	2.76e-05	0.00148	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—STAT3—psoriasis	2.52e-05	0.00135	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—TNF—psoriasis	2.18e-05	0.00117	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—VDR—psoriasis	2.15e-05	0.00115	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.14e-05	0.00115	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—VDR—psoriasis	2.11e-05	0.00113	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.06e-05	0.00111	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—VDR—psoriasis	1.99e-05	0.00107	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.87e-05	0.001	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IL6—psoriasis	1.76e-05	0.000945	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—CARM1—psoriasis	1.73e-05	0.000931	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—LEP—psoriasis	1.62e-05	0.00087	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.6e-05	0.000861	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—PPARG—psoriasis	1.5e-05	0.000805	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—PPARG—psoriasis	1.47e-05	0.000791	CbGpPWpGaD
Bexarotene—Epistaxis—Methotrexate—psoriasis	1.46e-05	0.000199	CcSEcCtD
Bexarotene—Paraesthesia—Prednisolone—psoriasis	1.46e-05	0.000199	CcSEcCtD
Bexarotene—Tachycardia—Triamcinolone—psoriasis	1.45e-05	0.000199	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.45e-05	0.000777	CbGpPWpGaD
Bexarotene—Malnutrition—Prednisone—psoriasis	1.44e-05	0.000198	CcSEcCtD
Bexarotene—Erythema—Prednisone—psoriasis	1.44e-05	0.000198	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Hydrocortisone—psoriasis	1.44e-05	0.000198	CcSEcCtD
Bexarotene—Hyperhidrosis—Triamcinolone—psoriasis	1.44e-05	0.000197	CcSEcCtD
Bexarotene—Feeling abnormal—Mycophenolate mofetil—psoriasis	1.43e-05	0.000196	CcSEcCtD
Bexarotene—Insomnia—Hydrocortisone—psoriasis	1.43e-05	0.000196	CcSEcCtD
Bexarotene—Hypertension—Betamethasone—psoriasis	1.43e-05	0.000196	CcSEcCtD
Bexarotene—Hypertension—Dexamethasone—psoriasis	1.43e-05	0.000196	CcSEcCtD
Bexarotene—Paraesthesia—Hydrocortisone—psoriasis	1.42e-05	0.000195	CcSEcCtD
Bexarotene—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	1.42e-05	0.000195	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.41e-05	0.000759	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—PPARG—psoriasis	1.41e-05	0.000758	CbGpPWpGaD
Bexarotene—Myalgia—Dexamethasone—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Myalgia—Betamethasone—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Abdominal pain—Cyclosporine—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Body temperature increased—Cyclosporine—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Anxiety—Betamethasone—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Anxiety—Dexamethasone—psoriasis	1.41e-05	0.000193	CcSEcCtD
Bexarotene—Vomiting—Mycophenolic acid—psoriasis	1.4e-05	0.000192	CcSEcCtD
Bexarotene—Discomfort—Betamethasone—psoriasis	1.39e-05	0.000191	CcSEcCtD
Bexarotene—Discomfort—Dexamethasone—psoriasis	1.39e-05	0.000191	CcSEcCtD
Bexarotene—Dyspepsia—Hydrocortisone—psoriasis	1.39e-05	0.000191	CcSEcCtD
Bexarotene—Haemoglobin—Methotrexate—psoriasis	1.39e-05	0.000191	CcSEcCtD
Bexarotene—Rash—Mycophenolic acid—psoriasis	1.39e-05	0.00019	CcSEcCtD
Bexarotene—Dermatitis—Mycophenolic acid—psoriasis	1.39e-05	0.00019	CcSEcCtD
Bexarotene—Pain—Prednisolone—psoriasis	1.39e-05	0.00019	CcSEcCtD
Bexarotene—RXRB—Gene Expression—PPARG—psoriasis	1.39e-05	0.000744	CbGpPWpGaD
Bexarotene—Haemorrhage—Methotrexate—psoriasis	1.39e-05	0.00019	CcSEcCtD
Bexarotene—Headache—Mycophenolic acid—psoriasis	1.38e-05	0.000189	CcSEcCtD
Bexarotene—Decreased appetite—Hydrocortisone—psoriasis	1.38e-05	0.000189	CcSEcCtD
Bexarotene—Pharyngitis—Methotrexate—psoriasis	1.37e-05	0.000188	CcSEcCtD
Bexarotene—Abdominal pain—Mycophenolate mofetil—psoriasis	1.37e-05	0.000188	CcSEcCtD
Bexarotene—Body temperature increased—Mycophenolate mofetil—psoriasis	1.37e-05	0.000188	CcSEcCtD
Bexarotene—Urinary tract disorder—Methotrexate—psoriasis	1.37e-05	0.000187	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Hydrocortisone—psoriasis	1.37e-05	0.000187	CcSEcCtD
Bexarotene—Fatigue—Hydrocortisone—psoriasis	1.36e-05	0.000187	CcSEcCtD
Bexarotene—Urethral disorder—Methotrexate—psoriasis	1.36e-05	0.000186	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Triamcinolone—psoriasis	1.36e-05	0.000186	CcSEcCtD
Bexarotene—Pain—Hydrocortisone—psoriasis	1.35e-05	0.000185	CcSEcCtD
Bexarotene—Oedema—Dexamethasone—psoriasis	1.35e-05	0.000185	CcSEcCtD
Bexarotene—Oedema—Betamethasone—psoriasis	1.35e-05	0.000185	CcSEcCtD
Bexarotene—RXRA—Metabolism—CARM1—psoriasis	1.35e-05	0.000724	CbGpPWpGaD
Bexarotene—Insomnia—Triamcinolone—psoriasis	1.35e-05	0.000185	CcSEcCtD
Bexarotene—Infection—Betamethasone—psoriasis	1.34e-05	0.000184	CcSEcCtD
Bexarotene—Infection—Dexamethasone—psoriasis	1.34e-05	0.000184	CcSEcCtD
Bexarotene—Ill-defined disorder—Prednisone—psoriasis	1.34e-05	0.000183	CcSEcCtD
Bexarotene—Paraesthesia—Triamcinolone—psoriasis	1.34e-05	0.000183	CcSEcCtD
Bexarotene—Feeling abnormal—Prednisolone—psoriasis	1.34e-05	0.000183	CcSEcCtD
Bexarotene—Anaemia—Prednisone—psoriasis	1.33e-05	0.000183	CcSEcCtD
Bexarotene—Shock—Betamethasone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Shock—Dexamethasone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Dyspnoea—Triamcinolone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Nervous system disorder—Betamethasone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Nervous system disorder—Dexamethasone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Agitation—Prednisone—psoriasis	1.33e-05	0.000182	CcSEcCtD
Bexarotene—Thrombocytopenia—Betamethasone—psoriasis	1.32e-05	0.000181	CcSEcCtD
Bexarotene—Thrombocytopenia—Dexamethasone—psoriasis	1.32e-05	0.000181	CcSEcCtD
Bexarotene—Tachycardia—Dexamethasone—psoriasis	1.32e-05	0.000181	CcSEcCtD
Bexarotene—Tachycardia—Betamethasone—psoriasis	1.32e-05	0.000181	CcSEcCtD
Bexarotene—Hypersensitivity—Cyclosporine—psoriasis	1.31e-05	0.00018	CcSEcCtD
Bexarotene—Dyspepsia—Triamcinolone—psoriasis	1.31e-05	0.00018	CcSEcCtD
Bexarotene—Nausea—Mycophenolic acid—psoriasis	1.31e-05	0.000179	CcSEcCtD
Bexarotene—Hyperhidrosis—Dexamethasone—psoriasis	1.31e-05	0.000179	CcSEcCtD
Bexarotene—Hyperhidrosis—Betamethasone—psoriasis	1.31e-05	0.000179	CcSEcCtD
Bexarotene—Feeling abnormal—Hydrocortisone—psoriasis	1.3e-05	0.000179	CcSEcCtD
Bexarotene—Malaise—Prednisone—psoriasis	1.3e-05	0.000178	CcSEcCtD
Bexarotene—Vertigo—Prednisone—psoriasis	1.3e-05	0.000178	CcSEcCtD
Bexarotene—Eye disorder—Methotrexate—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Gastrointestinal pain—Hydrocortisone—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Syncope—Prednisone—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Tinnitus—Methotrexate—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Anorexia—Betamethasone—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Anorexia—Dexamethasone—psoriasis	1.29e-05	0.000177	CcSEcCtD
Bexarotene—Cardiac disorder—Methotrexate—psoriasis	1.29e-05	0.000176	CcSEcCtD
Bexarotene—Fatigue—Triamcinolone—psoriasis	1.28e-05	0.000176	CcSEcCtD
Bexarotene—Hypersensitivity—Mycophenolate mofetil—psoriasis	1.28e-05	0.000175	CcSEcCtD
Bexarotene—Asthenia—Cyclosporine—psoriasis	1.28e-05	0.000175	CcSEcCtD
Bexarotene—Pain—Triamcinolone—psoriasis	1.27e-05	0.000175	CcSEcCtD
Bexarotene—Loss of consciousness—Prednisone—psoriasis	1.27e-05	0.000174	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.26e-05	0.000677	CbGpPWpGaD
Bexarotene—Pruritus—Cyclosporine—psoriasis	1.26e-05	0.000173	CcSEcCtD
Bexarotene—Angiopathy—Methotrexate—psoriasis	1.26e-05	0.000172	CcSEcCtD
Bexarotene—Abdominal pain—Hydrocortisone—psoriasis	1.25e-05	0.000171	CcSEcCtD
Bexarotene—Body temperature increased—Hydrocortisone—psoriasis	1.25e-05	0.000171	CcSEcCtD
Bexarotene—Asthenia—Mycophenolate mofetil—psoriasis	1.25e-05	0.000171	CcSEcCtD
Bexarotene—Hypertension—Prednisone—psoriasis	1.25e-05	0.000171	CcSEcCtD
Bexarotene—Chills—Methotrexate—psoriasis	1.24e-05	0.00017	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—TYK2—psoriasis	1.24e-05	0.000664	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Dexamethasone—psoriasis	1.23e-05	0.000169	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Betamethasone—psoriasis	1.23e-05	0.000169	CcSEcCtD
Bexarotene—Pruritus—Mycophenolate mofetil—psoriasis	1.23e-05	0.000168	CcSEcCtD
Bexarotene—Myalgia—Prednisone—psoriasis	1.23e-05	0.000168	CcSEcCtD
Bexarotene—Arthralgia—Prednisone—psoriasis	1.23e-05	0.000168	CcSEcCtD
Bexarotene—Feeling abnormal—Triamcinolone—psoriasis	1.23e-05	0.000168	CcSEcCtD
Bexarotene—Anxiety—Prednisone—psoriasis	1.22e-05	0.000168	CcSEcCtD
Bexarotene—Alopecia—Methotrexate—psoriasis	1.22e-05	0.000168	CcSEcCtD
Bexarotene—Insomnia—Betamethasone—psoriasis	1.22e-05	0.000168	CcSEcCtD
Bexarotene—Insomnia—Dexamethasone—psoriasis	1.22e-05	0.000168	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	1.22e-05	0.000167	CcSEcCtD
Bexarotene—Diarrhoea—Cyclosporine—psoriasis	1.22e-05	0.000167	CcSEcCtD
Bexarotene—Paraesthesia—Dexamethasone—psoriasis	1.21e-05	0.000166	CcSEcCtD
Bexarotene—Paraesthesia—Betamethasone—psoriasis	1.21e-05	0.000166	CcSEcCtD
Bexarotene—Discomfort—Prednisone—psoriasis	1.21e-05	0.000166	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—NDUFA5—psoriasis	1.21e-05	0.000651	CbGpPWpGaD
Bexarotene—Erythema—Methotrexate—psoriasis	1.21e-05	0.000165	CcSEcCtD
Bexarotene—Malnutrition—Methotrexate—psoriasis	1.21e-05	0.000165	CcSEcCtD
Bexarotene—Hypersensitivity—Prednisolone—psoriasis	1.19e-05	0.000164	CcSEcCtD
Bexarotene—Dyspepsia—Dexamethasone—psoriasis	1.19e-05	0.000163	CcSEcCtD
Bexarotene—Dyspepsia—Betamethasone—psoriasis	1.19e-05	0.000163	CcSEcCtD
Bexarotene—Diarrhoea—Mycophenolate mofetil—psoriasis	1.19e-05	0.000163	CcSEcCtD
Bexarotene—Dysgeusia—Methotrexate—psoriasis	1.18e-05	0.000162	CcSEcCtD
Bexarotene—Body temperature increased—Triamcinolone—psoriasis	1.18e-05	0.000161	CcSEcCtD
Bexarotene—Dizziness—Cyclosporine—psoriasis	1.18e-05	0.000161	CcSEcCtD
Bexarotene—Oedema—Prednisone—psoriasis	1.18e-05	0.000161	CcSEcCtD
Bexarotene—Decreased appetite—Betamethasone—psoriasis	1.18e-05	0.000161	CcSEcCtD
Bexarotene—Decreased appetite—Dexamethasone—psoriasis	1.18e-05	0.000161	CcSEcCtD
Bexarotene—Infection—Prednisone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Dexamethasone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Betamethasone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Back pain—Methotrexate—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Hypersensitivity—Hydrocortisone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Fatigue—Dexamethasone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Fatigue—Betamethasone—psoriasis	1.17e-05	0.00016	CcSEcCtD
Bexarotene—Shock—Prednisone—psoriasis	1.16e-05	0.000159	CcSEcCtD
Bexarotene—Pain—Dexamethasone—psoriasis	1.16e-05	0.000158	CcSEcCtD
Bexarotene—Pain—Betamethasone—psoriasis	1.16e-05	0.000158	CcSEcCtD
Bexarotene—Nervous system disorder—Prednisone—psoriasis	1.15e-05	0.000158	CcSEcCtD
Bexarotene—Tachycardia—Prednisone—psoriasis	1.15e-05	0.000157	CcSEcCtD
Bexarotene—Dizziness—Mycophenolate mofetil—psoriasis	1.15e-05	0.000157	CcSEcCtD
Bexarotene—Skin disorder—Prednisone—psoriasis	1.14e-05	0.000157	CcSEcCtD
Bexarotene—Hyperhidrosis—Prednisone—psoriasis	1.14e-05	0.000156	CcSEcCtD
Bexarotene—Asthenia—Hydrocortisone—psoriasis	1.14e-05	0.000156	CcSEcCtD
Bexarotene—Vomiting—Cyclosporine—psoriasis	1.13e-05	0.000155	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.13e-05	0.000607	CbGpPWpGaD
Bexarotene—Rash—Cyclosporine—psoriasis	1.12e-05	0.000154	CcSEcCtD
Bexarotene—Anorexia—Prednisone—psoriasis	1.12e-05	0.000154	CcSEcCtD
Bexarotene—Dermatitis—Cyclosporine—psoriasis	1.12e-05	0.000154	CcSEcCtD
Bexarotene—Pruritus—Hydrocortisone—psoriasis	1.12e-05	0.000153	CcSEcCtD
Bexarotene—Ill-defined disorder—Methotrexate—psoriasis	1.12e-05	0.000153	CcSEcCtD
Bexarotene—Headache—Cyclosporine—psoriasis	1.12e-05	0.000153	CcSEcCtD
Bexarotene—Anaemia—Methotrexate—psoriasis	1.11e-05	0.000153	CcSEcCtD
Bexarotene—Feeling abnormal—Betamethasone—psoriasis	1.11e-05	0.000153	CcSEcCtD
Bexarotene—Feeling abnormal—Dexamethasone—psoriasis	1.11e-05	0.000153	CcSEcCtD
Bexarotene—Gastrointestinal pain—Betamethasone—psoriasis	1.11e-05	0.000152	CcSEcCtD
Bexarotene—Gastrointestinal pain—Dexamethasone—psoriasis	1.11e-05	0.000152	CcSEcCtD
Bexarotene—Vomiting—Mycophenolate mofetil—psoriasis	1.1e-05	0.000151	CcSEcCtD
Bexarotene—Hypersensitivity—Triamcinolone—psoriasis	1.1e-05	0.00015	CcSEcCtD
Bexarotene—Rash—Mycophenolate mofetil—psoriasis	1.1e-05	0.00015	CcSEcCtD
Bexarotene—Dermatitis—Mycophenolate mofetil—psoriasis	1.09e-05	0.00015	CcSEcCtD
Bexarotene—Headache—Mycophenolate mofetil—psoriasis	1.09e-05	0.000149	CcSEcCtD
Bexarotene—Malaise—Methotrexate—psoriasis	1.09e-05	0.000149	CcSEcCtD
Bexarotene—Vertigo—Methotrexate—psoriasis	1.08e-05	0.000148	CcSEcCtD
Bexarotene—Diarrhoea—Hydrocortisone—psoriasis	1.08e-05	0.000148	CcSEcCtD
Bexarotene—Leukopenia—Methotrexate—psoriasis	1.08e-05	0.000148	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Prednisone—psoriasis	1.07e-05	0.000147	CcSEcCtD
Bexarotene—Dizziness—Prednisolone—psoriasis	1.07e-05	0.000147	CcSEcCtD
Bexarotene—Asthenia—Triamcinolone—psoriasis	1.07e-05	0.000147	CcSEcCtD
Bexarotene—Abdominal pain—Dexamethasone—psoriasis	1.07e-05	0.000146	CcSEcCtD
Bexarotene—Body temperature increased—Dexamethasone—psoriasis	1.07e-05	0.000146	CcSEcCtD
Bexarotene—Abdominal pain—Betamethasone—psoriasis	1.07e-05	0.000146	CcSEcCtD
Bexarotene—Body temperature increased—Betamethasone—psoriasis	1.07e-05	0.000146	CcSEcCtD
Bexarotene—Insomnia—Prednisone—psoriasis	1.07e-05	0.000146	CcSEcCtD
Bexarotene—Nausea—Cyclosporine—psoriasis	1.06e-05	0.000145	CcSEcCtD
Bexarotene—Paraesthesia—Prednisone—psoriasis	1.06e-05	0.000145	CcSEcCtD
Bexarotene—Pruritus—Triamcinolone—psoriasis	1.05e-05	0.000144	CcSEcCtD
Bexarotene—Cough—Methotrexate—psoriasis	1.05e-05	0.000144	CcSEcCtD
Bexarotene—Dizziness—Hydrocortisone—psoriasis	1.05e-05	0.000143	CcSEcCtD
Bexarotene—Dyspepsia—Prednisone—psoriasis	1.04e-05	0.000142	CcSEcCtD
Bexarotene—RXRA—Gene Expression—VDR—psoriasis	1.04e-05	0.000556	CbGpPWpGaD
Bexarotene—Nausea—Mycophenolate mofetil—psoriasis	1.03e-05	0.000141	CcSEcCtD
Bexarotene—CYP2C9—Metabolism—CYP2S1—psoriasis	1.03e-05	0.000553	CbGpPWpGaD
Bexarotene—Chest pain—Methotrexate—psoriasis	1.03e-05	0.000141	CcSEcCtD
Bexarotene—Myalgia—Methotrexate—psoriasis	1.03e-05	0.000141	CcSEcCtD
Bexarotene—Arthralgia—Methotrexate—psoriasis	1.03e-05	0.000141	CcSEcCtD
Bexarotene—Decreased appetite—Prednisone—psoriasis	1.02e-05	0.00014	CcSEcCtD
Bexarotene—Rash—Prednisolone—psoriasis	1.02e-05	0.00014	CcSEcCtD
Bexarotene—Dermatitis—Prednisolone—psoriasis	1.02e-05	0.00014	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.02e-05	0.00014	CcSEcCtD
Bexarotene—Fatigue—Prednisone—psoriasis	1.02e-05	0.000139	CcSEcCtD
Bexarotene—Headache—Prednisolone—psoriasis	1.02e-05	0.000139	CcSEcCtD
Bexarotene—Discomfort—Methotrexate—psoriasis	1.01e-05	0.000139	CcSEcCtD
Bexarotene—Constipation—Prednisone—psoriasis	1.01e-05	0.000138	CcSEcCtD
Bexarotene—Vomiting—Hydrocortisone—psoriasis	1.01e-05	0.000138	CcSEcCtD
Bexarotene—Rash—Hydrocortisone—psoriasis	9.98e-06	0.000137	CcSEcCtD
Bexarotene—Dermatitis—Hydrocortisone—psoriasis	9.97e-06	0.000137	CcSEcCtD
Bexarotene—Confusional state—Methotrexate—psoriasis	9.92e-06	0.000136	CcSEcCtD
Bexarotene—Headache—Hydrocortisone—psoriasis	9.92e-06	0.000136	CcSEcCtD
Bexarotene—Dizziness—Triamcinolone—psoriasis	9.86e-06	0.000135	CcSEcCtD
Bexarotene—Infection—Methotrexate—psoriasis	9.78e-06	0.000134	CcSEcCtD
Bexarotene—Feeling abnormal—Prednisone—psoriasis	9.7e-06	0.000133	CcSEcCtD
Bexarotene—Asthenia—Dexamethasone—psoriasis	9.7e-06	0.000133	CcSEcCtD
Bexarotene—Asthenia—Betamethasone—psoriasis	9.7e-06	0.000133	CcSEcCtD
Bexarotene—Nervous system disorder—Methotrexate—psoriasis	9.65e-06	0.000132	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—NFKB1—psoriasis	9.64e-06	0.000517	CbGpPWpGaD
Bexarotene—Thrombocytopenia—Methotrexate—psoriasis	9.64e-06	0.000132	CcSEcCtD
Bexarotene—Gastrointestinal pain—Prednisone—psoriasis	9.63e-06	0.000132	CcSEcCtD
Bexarotene—Nausea—Prednisolone—psoriasis	9.63e-06	0.000132	CcSEcCtD
Bexarotene—Pruritus—Betamethasone—psoriasis	9.57e-06	0.000131	CcSEcCtD
Bexarotene—Pruritus—Dexamethasone—psoriasis	9.57e-06	0.000131	CcSEcCtD
Bexarotene—Skin disorder—Methotrexate—psoriasis	9.56e-06	0.000131	CcSEcCtD
Bexarotene—Hyperhidrosis—Methotrexate—psoriasis	9.51e-06	0.00013	CcSEcCtD
Bexarotene—Vomiting—Triamcinolone—psoriasis	9.48e-06	0.00013	CcSEcCtD
Bexarotene—Nausea—Hydrocortisone—psoriasis	9.4e-06	0.000129	CcSEcCtD
Bexarotene—Rash—Triamcinolone—psoriasis	9.4e-06	0.000129	CcSEcCtD
Bexarotene—Dermatitis—Triamcinolone—psoriasis	9.39e-06	0.000129	CcSEcCtD
Bexarotene—Anorexia—Methotrexate—psoriasis	9.38e-06	0.000129	CcSEcCtD
Bexarotene—Headache—Triamcinolone—psoriasis	9.34e-06	0.000128	CcSEcCtD
Bexarotene—Abdominal pain—Prednisone—psoriasis	9.31e-06	0.000128	CcSEcCtD
Bexarotene—Body temperature increased—Prednisone—psoriasis	9.31e-06	0.000128	CcSEcCtD
Bexarotene—Diarrhoea—Betamethasone—psoriasis	9.25e-06	0.000127	CcSEcCtD
Bexarotene—Diarrhoea—Dexamethasone—psoriasis	9.25e-06	0.000127	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Methotrexate—psoriasis	8.97e-06	0.000123	CcSEcCtD
Bexarotene—Dizziness—Dexamethasone—psoriasis	8.94e-06	0.000123	CcSEcCtD
Bexarotene—Dizziness—Betamethasone—psoriasis	8.94e-06	0.000123	CcSEcCtD
Bexarotene—Insomnia—Methotrexate—psoriasis	8.9e-06	0.000122	CcSEcCtD
Bexarotene—Nausea—Triamcinolone—psoriasis	8.85e-06	0.000121	CcSEcCtD
Bexarotene—Paraesthesia—Methotrexate—psoriasis	8.84e-06	0.000121	CcSEcCtD
Bexarotene—Dyspnoea—Methotrexate—psoriasis	8.77e-06	0.00012	CcSEcCtD
Bexarotene—Somnolence—Methotrexate—psoriasis	8.75e-06	0.00012	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—VEGFA—psoriasis	8.75e-06	0.00047	CbGpPWpGaD
Bexarotene—Hypersensitivity—Prednisone—psoriasis	8.68e-06	0.000119	CcSEcCtD
Bexarotene—Dyspepsia—Methotrexate—psoriasis	8.66e-06	0.000119	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—STAT3—psoriasis	8.66e-06	0.000465	CbGpPWpGaD
Bexarotene—Vomiting—Betamethasone—psoriasis	8.6e-06	0.000118	CcSEcCtD
Bexarotene—Vomiting—Dexamethasone—psoriasis	8.6e-06	0.000118	CcSEcCtD
Bexarotene—Decreased appetite—Methotrexate—psoriasis	8.56e-06	0.000117	CcSEcCtD
Bexarotene—Rash—Dexamethasone—psoriasis	8.53e-06	0.000117	CcSEcCtD
Bexarotene—Rash—Betamethasone—psoriasis	8.53e-06	0.000117	CcSEcCtD
Bexarotene—Dermatitis—Dexamethasone—psoriasis	8.52e-06	0.000117	CcSEcCtD
Bexarotene—Dermatitis—Betamethasone—psoriasis	8.52e-06	0.000117	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Methotrexate—psoriasis	8.5e-06	0.000116	CcSEcCtD
Bexarotene—Fatigue—Methotrexate—psoriasis	8.49e-06	0.000116	CcSEcCtD
Bexarotene—Headache—Dexamethasone—psoriasis	8.47e-06	0.000116	CcSEcCtD
Bexarotene—Headache—Betamethasone—psoriasis	8.47e-06	0.000116	CcSEcCtD
Bexarotene—Asthenia—Prednisone—psoriasis	8.45e-06	0.000116	CcSEcCtD
Bexarotene—Pain—Methotrexate—psoriasis	8.42e-06	0.000115	CcSEcCtD
Bexarotene—Pruritus—Prednisone—psoriasis	8.33e-06	0.000114	CcSEcCtD
Bexarotene—RXRA—Metabolism—CAT—psoriasis	8.3e-06	0.000445	CbGpPWpGaD
Bexarotene—Feeling abnormal—Methotrexate—psoriasis	8.11e-06	0.000111	CcSEcCtD
Bexarotene—Diarrhoea—Prednisone—psoriasis	8.06e-06	0.00011	CcSEcCtD
Bexarotene—Gastrointestinal pain—Methotrexate—psoriasis	8.05e-06	0.00011	CcSEcCtD
Bexarotene—Nausea—Betamethasone—psoriasis	8.03e-06	0.00011	CcSEcCtD
Bexarotene—Nausea—Dexamethasone—psoriasis	8.03e-06	0.00011	CcSEcCtD
Bexarotene—CYP3A4—Metabolism—NDUFA5—psoriasis	8e-06	0.000429	CbGpPWpGaD
Bexarotene—Dizziness—Prednisone—psoriasis	7.79e-06	0.000107	CcSEcCtD
Bexarotene—Body temperature increased—Methotrexate—psoriasis	7.78e-06	0.000107	CcSEcCtD
Bexarotene—Abdominal pain—Methotrexate—psoriasis	7.78e-06	0.000107	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—TNF—psoriasis	7.5e-06	0.000402	CbGpPWpGaD
Bexarotene—Vomiting—Prednisone—psoriasis	7.49e-06	0.000103	CcSEcCtD
Bexarotene—Rash—Prednisone—psoriasis	7.43e-06	0.000102	CcSEcCtD
Bexarotene—Dermatitis—Prednisone—psoriasis	7.42e-06	0.000102	CcSEcCtD
Bexarotene—Headache—Prednisone—psoriasis	7.38e-06	0.000101	CcSEcCtD
Bexarotene—Hypersensitivity—Methotrexate—psoriasis	7.25e-06	9.94e-05	CcSEcCtD
Bexarotene—RXRA—Gene Expression—PPARG—psoriasis	7.22e-06	0.000388	CbGpPWpGaD
Bexarotene—Asthenia—Methotrexate—psoriasis	7.06e-06	9.68e-05	CcSEcCtD
Bexarotene—Nausea—Prednisone—psoriasis	7e-06	9.59e-05	CcSEcCtD
Bexarotene—Pruritus—Methotrexate—psoriasis	6.96e-06	9.54e-05	CcSEcCtD
Bexarotene—CYP3A4—Metabolism—CYP2S1—psoriasis	6.8e-06	0.000365	CbGpPWpGaD
Bexarotene—Diarrhoea—Methotrexate—psoriasis	6.73e-06	9.23e-05	CcSEcCtD
Bexarotene—Dizziness—Methotrexate—psoriasis	6.51e-06	8.92e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—APOE—psoriasis	6.45e-06	0.000346	CbGpPWpGaD
Bexarotene—Vomiting—Methotrexate—psoriasis	6.26e-06	8.57e-05	CcSEcCtD
Bexarotene—Rash—Methotrexate—psoriasis	6.21e-06	8.5e-05	CcSEcCtD
Bexarotene—Dermatitis—Methotrexate—psoriasis	6.2e-06	8.5e-05	CcSEcCtD
Bexarotene—Headache—Methotrexate—psoriasis	6.17e-06	8.45e-05	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—IL6—psoriasis	6.05e-06	0.000325	CbGpPWpGaD
Bexarotene—Nausea—Methotrexate—psoriasis	5.85e-06	8.01e-05	CcSEcCtD
Bexarotene—RXRA—Metabolism—PPARG—psoriasis	5.61e-06	0.000301	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.4e-06	0.00029	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CARM1—psoriasis	5.04e-06	0.00027	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.71e-06	0.000253	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CARM1—psoriasis	3.32e-06	0.000178	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CAT—psoriasis	3.1e-06	0.000166	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—APOE—psoriasis	2.41e-06	0.000129	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PPARG—psoriasis	2.1e-06	0.000113	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CAT—psoriasis	2.04e-06	0.00011	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—APOE—psoriasis	1.59e-06	8.52e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PPARG—psoriasis	1.38e-06	7.42e-05	CbGpPWpGaD
